Mucoadhesive drug delivery devices and methods of making and using thereof
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/08
A61K-039/12
A61K-009/20
A61K-038/00
A61K-048/00
A61K-031/557
출원번호
US-0007053
(2004-12-08)
등록번호
US-8529939
(2013-09-10)
발명자
/ 주소
Masters, David B.
Berg, Eric P.
출원인 / 주소
Gel-Del Technologies, Inc.
대리인 / 주소
Patterson Thuente Pedersen, P.A.
인용정보
피인용 횟수 :
49인용 특허 :
92
초록▼
The present invention relates to mucoadhesive drug delivery devices and their methods of preparation and use. More specifically the present invention relates to mucoadhesive drug delivery devices comprising one or more biocompatible purified proteins combined with one or more biocompatible solvents
The present invention relates to mucoadhesive drug delivery devices and their methods of preparation and use. More specifically the present invention relates to mucoadhesive drug delivery devices comprising one or more biocompatible purified proteins combined with one or more biocompatible solvents and one or more mucoadhesive agents. The mucoadhesive drug delivery devices may also include one or more pharmacologically active agents. The drug delivery devices of the present invention adhere to mucosal tissue, thereby providing a vehicle for delivery of the pharmacologically active agent(s) through such tissue.
대표청구항▼
1. A mucoadhesive device, comprising one or more purified free-form proteins, wherein one of the purified proteins included in the mucoadhesive device is ovalbumin, combined with one or more pharmacologically active agents, one or more mucoadhesive agents and one or more biocompatible solvents forme
1. A mucoadhesive device, comprising one or more purified free-form proteins, wherein one of the purified proteins included in the mucoadhesive device is ovalbumin, combined with one or more pharmacologically active agents, one or more mucoadhesive agents and one or more biocompatible solvents formed into a cohesive body or solidified cohesive mass that is formed into a mucoadhesive device and having the purified proteins in an amount of about 15% to 85% by weight of the mucoadhesive device, and the mucoadhesive agents in an amount of about 0.1% to 35% by weight of the mucoadhesive device, wherein the mucoadhesive device is configured to have a form such that the mucoadhesive device is capable of adhering to mucosal tissue of a patient for the delivery of the one or more pharmacologically active agents to the patient. 2. The mucoadhesive device of claim 1, wherein the mucoadhesive device further includes one or more additional purified proteins selected from the group consisting of elastin, collagen, albumin, plakalbumin, lactalbumin, glycomacropeptide, lactoglobulin, prealbumin, glutamine oligopeptide, casein, keratin, fibronectin, silk, silk fibroin, actin, myosin, fibrinogen, thrombin, aprotinin, antithrombin III, whey protein, betalactoglobulin, alphlactalbumin, rice protein, grape vine protein, grape leaf protein, maize protein, olive protein, canola protein, soy protein, cottonseed protein, cotton leaf protein, seaweed protein, wheat protein, agglutinen, tobacco proteins, F1 and F2 protein, chickpea protein, fish protein and combinations thereof. 3. The mucoadhesive device of claim 1, wherein the biocompatible solvent is selected from the group consisting of water; saline; dimethyl sulfoxide (DMSO); methanol, ethanol, formic acid, olive oil, peanut oil and combinations thereof. 4. The mucoadhesive device of claim 3, wherein the biocompatible solvent is water. 5. The mucoadhesive device of claim 1, wherein the mucoadhesive agents are selected from the group consisting of glycerol, pectin, polyethylene glycol, sorbitol, maltitol, mannitol, hydrogenated glucose syrups, xylitol, polydextrose, glyceryl triacetate, propylene glycol, propylene glycol alginate, glycogen and combinations thereof. 6. The mucoadhesive device of claim 1, wherein the mucoadhesive agent is glycerol. 7. The mucoadhesive device of claim 1, further including an additive wherein the additive is selected from the group consisting of polyurethanes, vinyl homopolymers and copolymers, acrylate homopolymers and copolymers, polyethers, cellulosics, epoxies, polyesters, acrylics, nylons, silicones, polyanhydride, poly(ethylene terephthalate), polyacetal, poly(lactic acid), poly(ethylene oxide)/poly(butylene terephthalate) copolymer, polycarbonate, poly(tetrafluoroethylene) (PTFE), polycaprolactone, polyethylene oxide, poly(vinyl chloride), polylactic acid, polyglycolic acid, polypropylene oxide, poly(akylene)glycol, polyoxyethylene, sebacic acid, polyvinyl alcohol (PVA), 2-hydroxyethyl methacrylate (HEMA), polymethyl methacrylate, 1,3-bis(carboxyphenoxy)propane, lipids, phosphatidylcholine, triglycerides, polyhydroxybutyrate (PHB), polyhydroxyvalerate (PHV), poly(ethylene oxide) (PEO), poly ortho esters, poly (amino acids), polycynoacrylates, polyphophazenes, polysulfone, polyamine, poly (amido amines), fibrin, graphite, flexible fluoropolymer, isobutyl-based, isopropyl styrene, vinyl pyrrolidone, cellulose acetate dibutyrate, silicone rubber, ceramics, bioceramics, glasses bioglasses, glass-ceramics, resin cement, resin fill, glass ionomer, hydroxyapatite, calcium sulfate, Al2O3, tricalcium phosphate, calcium phosphate salts, sugars, starches, carbohydrates, salts, polysaccharides, alginate, carbon, cobalt-based alloys, galvanic-based alloys, stainless steel-based alloys, titanium- based alloys, zirconium oxide, zirconia, silica, aluminum-based alloys, vanadium-based alloys, molybdenum-based alloys, nickel-based alloys, iron-based alloys, zinc phosphate, zinc polycarboxylate and combinations thereof. 8. The mucoadhesive device of claim 1, wherein the pharmacologically active agent is selected from the group consisting of proteins, peptides, polysaccharides, nucleic acids, oligonucleotides, steroids, cytotoxic agents, analgesics, antiinflammatories, anesthetics, aminoglycosides, dermatological agents, antiviral, antibiotics, antimicrobials, vesicles, antibodies, vitamins, cofactors, viruses, microorganisms, cells, blood clotting factors, clot inhibitors, clot dissolving agents, tissues, antiestrogens, antigens, antiandrogens, muscle relaxants, prostaglandins, iodine compounds, nutritional agents, allergens, protease inhibitors, antirheumatoid agents, obstetric drugs, ovulation inducers, diuretics, antidiuretics, antihistamines, ceramides, antifungals, quinolones, sulfa drugs, neuromuscular blocking agents, anticonvulsants, CNS stimulants, antianxiety drugs, neuroleptics, antidepressants, sedatives, hemostatic agents, vasodilators, adrenergic stimulants, antimigraine drugs, cardiotonic glycosides, beta-adrenergic blocking agents, antiangina agents, antiarrhyrthmics, calcium channel blockers, sodium channel blockers, antihypertensives, anticoagulants, thrombolytic agents, antipyretics, anti-alzheimer's agents, anti-Parkinson's agents, antiemetics, reductase inhibitors, pituitary hormones, thyroid hormones, hypoglycemic agents, hormones, antimalarials, anoretic agents, hypercalcemia, antitussives, expectorants, decongestants, bronchospasm relaxants, smoking cessation agents, vaccines and any combination or prodrugs thereof. 9. The mucoadhesive device of claim 1, wherein the one or more purified proteins is ovalbumin, the one or more biocompatible solvents is water and the one or more mucoadhesive agents is glycerol. 10. The mucoadhesive device of claim 9, wherein the one or more pharmacologically active agents are selected from the group consisting of peptides, antisense, anesthetics, analgesics, chemotherapy agents, antidiuretics, anti-inflammatories and neurotoxins. 11. The mucoadhesive device of claim 1, wherein the one or more biocompatible solvents are selected from the group consisting of water, saline and DMSO. 12. The mucoadhesive device of claim 1, wherein the cohesive body is compressed and formed into a wafer, tablet, cylinder, sheet or sphere. 13. The mucoadhesive device of claim 1, wherein the cohesive body is compressed and processed into particles. 14. The mucoadhesive device of claim 1, wherein the solidified cohesive mass is processed into particles. 15. The mucoadhesive device of claim 14, wherein a plurality of the particles are compressed into a mucoadhesive mass. 16. The mucoadhesive device of claim 15, wherein the mass is a tablet, sphere, cylinder, sheet or wafer. 17. A mucoadhesive device, comprising ovalbumin in a free-form state, combined with one or more pharmacologically active agents, one or more mucoadhesive agents and one or more biocompatible solvents and formed into a cohesive body or solidified cohesive mass that is formed into a mucoadhesive device having a homogenous distribution of the ovalbumin in an amount of about 15% to 85% by weight of the mucoadhesive device, pharmacologically active agents, mucoadhesive agents in an amount of about 0.1% to 35% by weight of the mucoadhesive device and biocompatible solvents, wherein the mucoadhesive device is configured to have a form such that the mucoadhesive device is capable of adhering to mucosal tissue of a patient for the delivery of the one or more pharmacologically active agents to the patient. 18. The mucoadhesive device of claim 17, wherein the biocompatible solvent is selected from the group consisting of water; saline; dimethyl sulfoxide (DMSO); methanol, ethanol, formic acid, olive oil, peanut oil and combinations thereof. 19. The mucoadhesive device of claim 18, wherein the biocompatible solvent is water. 20. The mucoadhesive device of claim 17, wherein the mucoadhesive agents are selected from the group consisting of glycerol, pectin, polyethylene glycol, sorbitol, maltitol, mannitol, hydrogenated glucose syrups, xylitol, polydextrose, glyceryl triacetate, propylene glycol, propylene glycol alginate, glycogen and combinations thereof. 21. The mucoadhesive device of claim 20, wherein the mucoadhesive agents is glycerol. 22. The mucoadhesive device of claim 17, further including an additive wherein the additive is selected from the group consisting of polyurethanes, vinyl homopolymers and copolymers, acrylate homopolymers and copolymers, polyethers, cellulosics, epoxies, polyesters, acrylics, nylons, silicones, polyanhydride, poly(ethylene terephthalate), polyacetal, poly(lactic acid), poly(ethylene oxide)/poly(butylene terephthalate) copolymer, polycarbonate, poly(tetrafluoroethylene) (PTFE), polycaprolactone, polyethylene oxide, poly(vinyl chloride), polylactic acid, polyglycolic acid, polypropylene oxide, poly(akylene)glycol, polyoxyethylene, sebacic acid, polyvinyl alcohol (PVA), 2-hydroxyethyl methacrylate (HEMA), polymethyl methacrylate, 1,3-bis(carboxyphenoxy)propane, lipids, phosphatidylcholine, triglycerides, polyhydroxybutyrate (PHB), polyhydroxyvalerate (PHV), poly(ethylene oxide) (PEO), poly ortho esters, poly (amino acids), polycynoacrylates, polyphophazenes, polysulfone, polyamine, poly (amido amines), fibrin, graphite, flexible fluoropolymer, isobutyl-based, isopropyl styrene, vinyl pyrrolidone, cellulose acetate dibutyrate, silicone rubber, ceramics, bioceramics, glasses bioglasses, glass-ceramics, resin cement, resin fill, glass ionomer, hydroxyapatite, calcium sulfate, Al2O3, tricalcium phosphate, calcium phosphate salts, sugars, starches, carbohydrates, salts, polysaccharides, alginate, carbon, cobalt-based alloys, galvanic-based alloys, stainless steel-based alloys, titanium-based alloys, zirconium oxide, zirconia, silica, aluminum-based alloys, vanadium-based alloys, molybdenum-based alloys, nickel-based alloys, iron-based alloys, zinc phosphate, zinc polycarboxylate and combinations thereof. 23. The mucoadhesive device of claim 17, wherein the pharmacologically active agent is selected from the group consisting of proteins, peptides, polysaccharides, nucleic acids, oligonucleotides, steroids, cytotoxic agents, analgesics, antiinflammatories, anesthetics, aminoglycosides, dermatological agents, antiviral, antibiotics, antimicrobials, vesicles, antibodies, vitamins, cofactors, viruses, microorganisms, cells, blood clotting factors, clot inhibitors, clot dissolving agents, tissues, antiestrogens, antigens, antiandrogens, muscle relaxants, prostaglandins, iodine compounds, nutritional agents, allergens, protease inhibitors, antirheumatoid agents, obstetric drugs, ovulation inducers, diuretics, antidiuretics, antihistamines, ceramides, antifungals, quinolones, sulfa drugs, neuromuscular blocking agents, anticonvulsants, CNS stimulants, antianxiety drugs, neuroleptics, antidepressants, sedatives, hemostatic agents, vasodilators, adrenergic stimulants, antimigraine drugs, cardiotonic glycosides, beta-adrenergic blocking agents, antiangina agents, antiarrhyrthmics, calcium channel blockers, sodium channel blockers, antihypertensives, anticoagulants, thrombolytic agents, antipyretics, anti-alzheimer's agents, anti-Parkinson's agents, antiemetics, reductase inhibitors, pituitary hormones, thyroid hormones, hypoglycemic agents, hormones, antimalarials, anoretic agents, hypercalcemia, antitussives, expectorants, decongestants, bronchospasm relaxants, smoking cessation agents, vaccines and any combination or prodrugs thereof. 24. The mucoadhesive device of claim 17, wherein the one or more biocompatible solvents is water and the one or more mucoadhesive agents is glycerol. 25. The mucoadhesive device of claim 17, wherein the one or more pharmacologically active agents are selected from the group consisting of peptides, antisense, anesthetics, analgesics, chemotherapy agents, antidiuretics, anti-inflammatories and neurotoxins. 26. The mucoadhesive device of claim 17, wherein the cohesive body is compressed. 27. The mucoadhesive device of claim 16, wherein the compressed cohesive body is formed into a wafer, tablet, cylinder, sheet or sphere. 28. The mucoadhesive device of claim 17, wherein the compressed cohesive body is processed into particles. 29. The mucoadhesive device of claim 17, wherein the solidified cohesive mass is processed into particles. 30. The mucoadhesive device of claim 28, wherein a plurality of the particles are compressed into a tablet, sphere, cylinder, sheet or wafer. 31. The mucoadhesive device of claim 29, wherein a plurality of the particles are compressed into a tablet, sphere, cylinder, sheet or wafer. 32. A method of delivering one or more pharmacologically active agents through the mucosal tissue of a patient comprising the steps of: adhering a mucoadhesive device to the mucosal tissue of a patient, said mucoadhesive device including one or more purified free-form proteins, wherein one of the purified proteins included in the mucoadhesive device is ovalbumin, combined with one or more pharmacologically active agents, one or more mucoadhesive agents and one or more biocompatible solvents to form a coatable composition, wherein the solvent content of the coatable composition is reduced and formed into a mucoadhesive device having a homogenous distribution of the purified proteins, pharmacologically active agents, mucoadhesive agents and biocompatible solvents, wherein the mucoadhesive device is configured to have a form such that the mucoadhesive device adheres to the mucosal tissue of the patient for the delivery of the one or more pharmacologically active agents to the patient. 33. The method of delivering one or more pharmacologically active agents through mucosal tissue of a patient of claim 32, wherein the mucosal tissue is located at the cheek, gum, sublingual area, palate, tongue, periodontal pockets, nasal cavity, vaginal cavity, anal cavity, intestinal walls, pulmonary regions, ocular areas, or stomach cavity. 34. The method of delivering one or more pharmacologically active agents through mucosal tissue of a patient of claim 32, wherein the one or more biocompatible solvents is water and the one or more mucoadhesive agents is glycerol. 35. The method of delivering one or more pharmacologically active agents through mucosal tissue of a patient of claim 32, wherein the one or more pharmacologically active agents are selected from the group consisting of peptides, antisense, anesthetics, analgesics, chemotherapy agents, antidiuretics, anti-inflammatories, neurotoxins and vitamins. 36. The method of delivering one or more pharmacologically active agents through mucosal tissue of a patient of claim 32, where the mucoadhesive device is in a form selected from the group consisting of a wafer, tablet, cylinder, sheet, particles or sphere. 37. A method of making a mucoadhesive drug delivery device comprising: (a) preparing a coatable composition including one or more biocompatible purified free-form proteins, wherein one of the purified proteins included in the mucoadhesive device is ovalbumin, one or more biocompatible solvents, one or more mucoadhesive agents and one or more pharmacologically active agents;(b) partially drying the coatable composition to reduce bulk solvent present in the system to form a solidified cohesive mass including a substantially homogenous distribution of purified proteins, solvents, mucoadhesive agents and pharmacologically active agents; and(c) processing the cohesive mass to form a mucoadhesive device, wherein the mucoadhesive device is processed to have a form such that the mucoadhesive device is capable of adhering to mucosal tissue of a patient for the delivery of the one or more pharmacologically active agents to the patient. 38. The method of making a mucoadhesive drug delivery device of claim 37, wherein the one or more biocompatible solvents is water and the one or more mucoadhesive agents is glycerol. 39. The method of making a mucoadhesive drug delivery device of claim 37, wherein the one or more pharmacologically active agents are selected from the group consisting of peptides, antisense, anesthetics, analgesics, chemotherapy agents, antidiuretics, anti-inflammatories, neurotoxins and vitamins. 40. The method of making a mucoadhesive drug delivery device of claim 37, wherein the mucoadhesive device is processed into a form selected from the group consisting of a wafer, tablet, cylinder, sheet, particles or sphere.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (92)
Harvey Wilson (Sterling GBX) Light Nicholas D. (Doune Perthshire GBX) Haynes Carla A. (Glasgow GBX), Absorbable composite materials for use in the treatment of periodontal disease.
Rel Bernhard (Knigstein/Taunus DEX) Petri Walter (Niedernhausen/Taunus DEX), Base for mucosal and denture adhesive pastes, a process for the preparation thereof, and pastes having this base.
Schiraldi Michael T. (East Brunswick NJ) Perl Martin M. (Brooklyn NY) Rubin Howard (Rockaway NJ), Bioadhesive extruded film for intra-oral drug delivery and process.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Biologically inert, biocompatible-polymer conjugates.
Collombel Christian (Lyon FRX) Damour Odile (Saint Genis Laval FRX) Gagnieu Christian (Lyon FRX) Poinsignon Frederique (Lyon FRX) Echinard Christian (Gemenos FRX) Marichy Jacques (Lyon FRX), Biomaterials with a base of mixtures of collagen, chitosan and glycosaminoglycans, process for preparing them and their.
Brendel Klaus (Tucson AZ) Duhamel Raymond C. (Tucson AZ), Body implants of extracellular matrix and means and methods of making and using such implants.
Kaplan Donald S. (Weston CT) Muth Ross R. (Brookfield CT) Totakura Nagabhushanam (Norwalk CT) Zinner Darren E. (Norwalk CT) Stone Corbett W. (Newtown CT), Compositions, methods and apparatus for inhibiting fogging of endoscope lenses.
Phipps Joseph B. (Plymouth MN) Howland Warren W. (Champlin MN) Jevne Allan H. (Anoka MN) Holmblad Carolann (Cambridge MN), Device and method for iontophoretic drug delivery.
Amundson Rodney R. (Lindstrom MN) Hull Vincent W. (Ham Lake MN) Dror Michael (Edina MN) Schwartz Robert S. (Rochester MN), Drug delivery balloon catheter with line of weakness.
David B. Masters, Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices.
Hubbell Jeffrey A. (Austin TX) Pathak Chandrashekhar P. (Waltham MA) Sawhney Amarpreet S. (Newton MA) Desai Neil P. (Los Angeles CA) Hill-West Jennifer L. (Austin TX) Hossainy Syed F. A. (Austin TX), Gels for encapsulation of biological materials.
Folkman Judah (Brookline MA) Langer ; Jr. Robert S. (Somerville MA) Hsieh Dean S. T. (Cambridge MA), Magnetically modulated polymeric drug release system.
Wahlig Helmut (Darmstadt DEX) Dingeldain Elvira (Dreieich DEX) Braun Dietrich (Darmstadt-Arheilgen DEX), Medicinally useful, shaped mass of collagen resorbable in the body.
Nagai Tsuneji (Chofu JPX) Machida Yoshiharu (Kawasaki JPX) Suzuki Yoshiki (Hino JPX) Ikura Hiroshi (Hino JPX), Method and preparation for administration to the mucosa of the oral or nasal cavity.
Nagai Tsuneji (Chofu JPX) Machida Yoshiharu (Kawasaki JPX) Suzuki Yoshiki (Hino JPX) Ikura Hiroshi (Hino JPX), Method and preparation for administration to the mucosa of the oral or nasal cavity.
Dinh Thomas Q. (5319 Baker Rd. Minnetonka MN) Tuch Ronald J. (12330 51st Ave. N. Plymouth MN) Dror Michael (6227 Westridge Blvd. Edina MN), Method of making an intraluminal stent.
Kizawa Hidenori (Tokyo JPX) Fujiyama Norimasa (Tokyo JPX) Kobayashi Jitsuo (Kanagawa JPX) Ito Akinori (Niigata JPX), Mucous membrane-adhering film preparation and process for its preparation.
Song Suk-Zu (Moorpark CA) Morawiecki Andrew (Camarillo CA) Pierce Glenn F. (Thousand Oaks CA) Pitt Colin G. (Westlake Village CA), Multi-layered collagen film compositions for delivery of proteins and methods of using same.
Casey Donald J. (Ridgefield CT) Huffman Kenneth R. (Stamford CT), Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same.
Hyon Suong-Hyu (Uji JPX) Ikada Yoshita (Uji JPX), Polylactic acid type microspheres containing physiologically active substance and process for preparing the same.
Cha Younsik (Salt Lake City UT) Choi Young Kweon (Salt Lake City UT) Pai Chaul Min (Taejon KRX), Preparation of peptide containing biodegradable microspheres by melt process.
Suzuki Yoshiki (Hino JPX) Ikura Hiroshi (Hino JPX) Yamashita Gentaro (Koganei JPX), Slow-releasing medical preparation to be administered by adhering to a wet mucous surface.
Reiley Mark A ; Scholten Arie ; Talmadge Karen D ; Scribner Robert M, Systems and methods for treating fractured or diseased bone using expandable bodies.
Buysse Steven P. ; Kennedy Jenifer S. ; Lands Michael J. ; Loeffler Donald R. ; Lukianow S. Wade ; Ryan Thomas P., Vascular tissue sealing pressure control and method.
Biegajski James E. (Foster City CA) Venkatraman Subbu S. (Palo Alto CA) Scott Ann M. (Mountain View CA), Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavi.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; John, Matthias; Roy, Atanu; Whoriskey, Susan; Wood, Kristy M.; Hatala, Paul; Schrum, Jason P.; Ejebe, Kenechi; Ellsworth, Jeff Lynn; Guild, Justin, In vivo production of proteins.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; John, Matthias; Roy, Atanu; Whoriskey, Susan; Wood, Kristy M.; Hatala, Paul; Schrum, Jason P.; Ejebe, Kenechi; Ellsworth, Jeff Lynn; Guild, Justin, Modified polynucleotides for the production of biologics and proteins associated with human disease.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; John, Matthias; Roy, Atanu; Whoriskey, Susan; Wood, Kristy M.; Hatala, Paul; Schrum, Jason P.; Ejebe, Kenechi; Ellsworth, Jeff Lynn; Guild, Justin, Modified polynucleotides for the production of biologics and proteins associated with human disease.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; John, Matthias; Roy, Atanu; Whoriskey, Susan; Wood, Kristy M.; Hatala, Paul; Schrum, Jason P.; Ejebe, Kenechi; Ellsworth, Jeff Lynn; Guild, Justin, Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; John, Matthias; Roy, Atanu; Whoriskey, Susan; Wood, Kristy M.; Hatala, Paul; Schrum, Jason P.; Ejebe, Kenechi; Ellsworth, Jeff Lynn; Guild, Justin, Modified polynucleotides for the production of oncology-related proteins and peptides.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; Ellsworth, Jeff Lynn; Ejebe, Kenechi; Guild, Justin; John, Matthias; Hatala, Paul; Roy, Atanu; Schrum, Jason P.; Whoriskey, Susan; Wood, Kristy M., Modified polynucleotides for the production of proteins.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; John, Matthias; Roy, Atanu; Whoriskey, Susan; Wood, Kristy M.; Hatala, Paul; Schrum, Jason P.; Ejebe, Kenechi; Ellsworth, Jeff Lynn; Guild, Justin, Modified polynucleotides for the production of proteins.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; John, Matthias; Roy, Atanu; Whoriskey, Susan; Wood, Kristy M.; Hatala, Paul; Schrum, Jason P.; Ejebe, Kenechi; Ellsworth, Jeff Lynn; Guild, Justin, Modified polynucleotides for the production of proteins associated with human disease.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; John, Matthias; Roy, Atanu; Whoriskey, Susan; Wood, Kristy M.; Hatala, Paul; Schrum, Jason P.; Ejebe, Kenechi; Ellsworth, Jeff Lynn; Guild, Justin, Modified polynucleotides for the production of secreted proteins.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.